Design and Construction of Bidirectional Tumor-Specific Expression Vector to Silence or Over-expressSimultaneously in Cancer Gene Therapy
- سال انتشار: 1394
- محل انتشار: اولین سمپوزیوم بین المللی سرطان نسترن
- کد COI اختصاصی: NASTARANCANSER01_015
- زبان مقاله: انگلیسی
- تعداد مشاهده: 999
نویسندگان
PhD candidate in Medical Biotechnology, Semnan University of Medical Sciences, Semnan, Iran
Semnan Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran
Gorgan University of Agricultural Sciences and Natural Resources, Department of Plant Breeding andBiotechnology, Iran
Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
چکیده
Due to the drawbacks of small interfering RNA, and/or non-specific and low promoter activityof vector-based RNA polymerase III promoters, need to find and develop a novel therapy incancer. To specify and enhance the expression of vector-based RNAi, the tumor-specificpromoters are concerned. Survivin, a member of apoptosis inhibitor family, is exhibitingexclusive potential properties in cancer gene therapy. The aim of present study is to design anddevelop the survivin promoter in bidirectional, which is able to silence or over-express twogenes simultaneously. Promoter of survivin as RNA polymerase II promoter was elected. Usingbioinformatics tools, the core promoter sequence of survivin was selected and designed in twodirections. The 1100 nucleotide fragment was synthesized in GenScript, and subsequentlycloned in pRNAT-U6.1/Neo expression vector (6380 bp) as background. The substitution ofthe U6 promoter into the bidirection survivin core promoter was evaluated with doubledigestion analysis. To assess the efficiency of promoter activity, two shRNA oligonucleotideswas inserted in the downstream of each promoter and the QRT-PCR assay was conducted toestimate the mRNA expression level. The construction of tumor-specific expression vectorwith two shRNA (6888 bp) was verified by double digestion test. The expression of mRNAwas significantly reduced approximately 54% after treatment. The current recombinant vectoras an expression vector-based RNA polymerase II promoter can be applied for silencing and/orover-expression of two target genes. Hope to overcome the cancer via novel gene therapytechniques.کلیدواژه ها
Survivin, bidirection promoter, RNA polymerase II & III, cancer gene therapyمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.